Related Experiment Videos
Medroxyprogesterone acetate therapy in hirsutism.
The British Journal of Dermatology
|August 1, 1985
Summary
Medroxyprogesterone acetate (MPA) treatments for hirsutism showed varied results. Subcutaneous injection of MPA was most effective, reducing hair diameter and serum androgen levels, suggesting a dual action mechanism.
Area of Science:
- Endocrinology
- Dermatology
Background:
- Hirsutism affects numerous women, often linked to elevated androgen levels.
- Medroxyprogesterone acetate (MPA) is a progestin with potential anti-androgenic effects.
Purpose of the Study:
- To evaluate the efficacy of different medroxyprogesterone acetate (MPA) administration routes for treating hirsutism in females.
- To investigate the impact of MPA on hair diameter and serum androgen levels.
Main Methods:
- A pilot study involving 26 hirsute females.
- Comparison of three MPA treatment methods: topical ointment (0.2%), subcutaneous injection, and intramuscular injection.
- Treatment duration averaged 16 weeks.
Main Results:
- Subcutaneous injection yielded the best clinical improvement, followed by intramuscular injection; topical application was least effective.
- Average hair diameter reduction of 33% observed in 12 patients.
- Topical MPA did not affect serum androgen levels, while injections decreased them.
Conclusions:
- MPA demonstrates efficacy in treating hirsutism, with injection routes being superior to topical application.
- Clinical improvement from topical MPA suggests a local cellular mechanism.
- Injected MPA likely acts through both systemic androgen suppression and local effects.